C88.30
Immunoproliferative small intestinal disease not having achieved remission
Clinical Classification Guidelines
Inclusion Terms
- Alpha heavy chain disease NOS
- Alpha heavy chain disease not having achieved remission
- Alpha heavy chain disease with failed remission
- Immunoproliferative small intestinal disease NOS
- Immunoproliferative small intestinal disease with failed remission
- Mediterranean lymphoma NOS
- Mediterranean lymphoma not having achieved remission
- Mediterranean lymphoma with failed remission
Medical Intelligence & Overview
Immunoproliferative Small Intestinal Disease (IPSID) is a rare type of lymphoma that affects the small intestine. When this disease does not respond to treatment and remains active, it is classified under the ICD-10 code C88.30. The disease involves abnormal growth of immune cells, particularly those producing abnormal immunoglobulins, leading to intestinal problems and other systemic symptoms. Also known as Mediterranean lymphoma or alpha heavy chain disease, IPSID can be a challenging condition requiring ongoing medical attention.
Causes & Symptoms
Clinical Causes: Cause unknown in many cases, but certain factors can increase risk, including genetic predispositions and environmental influences. Infections, particularly with bacteria like *Campylobacter jejuni*, have been associated with the development of IPSID. Dietary factors and regional prevalence, especially in Mediterranean and Middle Eastern populations, are linked to higher incidences. Chronic intestinal inflammation may play a role in disease development.
Key Symptoms: Chronic diarrhea that may be persistent or relapsing. Malabsorption leading to weight loss and nutritional deficiencies. Abdominal pain or discomfort. Groin or abdominal masses in some cases. Weakness and fatigue due to anemia or nutritional deficiencies. Fever and night sweats in more advanced stages.
Diagnostic & Treatment
Diagnosis Path: Clinical evaluation of symptoms and medical history. Endoscopic examination of the small intestine to visualize abnormalities or masses. Biopsy during endoscopy to analyze tissue samples for abnormal lymphoid cells. Imaging tests such as CT scans or MRI to assess the extent of disease. Laboratory tests to detect abnormal immunoglobulin levels, specifically alpha heavy chains. Molecular and immunohistochemical studies to identify specific cellular characteristics.
Treatment Protocols: Chemotherapy regimens tailored to lymphoma types and disease extent. Antibiotic therapy if an infectious component, like *Campylobacter*, is suspected or confirmed. Immunotherapy approaches to boost immune response against abnormal cells. Supportive care, including nutritional support and management of symptoms. Surgical intervention may be considered in cases with localized intestinal complications or obstructions. Regular follow-up and monitoring to evaluate treatment response and disease progression.
Clinical Advice & FAQs
Billing Guidance
Is C88.30 a billable ICD-10 code?
Yes, C88.30 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C88.30?
Clinical documentation must specify the nature of Immunoproliferative small intestinal disease not having achieved remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference